515 related articles for article (PubMed ID: 28286997)
1. Antiviral activity of cationic amphiphilic drugs.
Salata C; Calistri A; Parolin C; Baritussio A; Palù G
Expert Rev Anti Infect Ther; 2017 May; 15(5):483-492. PubMed ID: 28286997
[TBL] [Abstract][Full Text] [Related]
2. Kinase Inhibitors as Underexplored Antiviral Agents.
García-Cárceles J; Caballero E; Gil C; Martínez A
J Med Chem; 2022 Jan; 65(2):935-954. PubMed ID: 33970631
[TBL] [Abstract][Full Text] [Related]
3. Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs.
Schor S; Einav S
DNA Cell Biol; 2018 Feb; 37(2):63-69. PubMed ID: 29148875
[TBL] [Abstract][Full Text] [Related]
4. Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry.
Mazzon M; Ortega-Prieto AM; Imrie D; Luft C; Hess L; Czieso S; Grove J; Skelton JK; Farleigh L; Bugert JJ; Wright E; Temperton N; Angell R; Oxenford S; Jacobs M; Ketteler R; Dorner M; Marsh M
Viruses; 2019 Feb; 11(2):. PubMed ID: 30791609
[TBL] [Abstract][Full Text] [Related]
5. Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli B; Palù G; Loregian A
Trends Microbiol; 2018 Oct; 26(10):865-876. PubMed ID: 29759926
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
7. Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis.
Prochnow H; Rox K; Birudukota NVS; Weichert L; Hotop SK; Klahn P; Mohr K; Franz S; Banda DH; Blockus S; Schreiber J; Haid S; Oeyen M; Martinez JP; Süssmuth RD; Wink J; Meyerhans A; Goffinet C; Messerle M; Schulz TF; Kröger A; Schols D; Pietschmann T; Brönstrup M
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666384
[TBL] [Abstract][Full Text] [Related]
8. Integrated human-virus metabolic stoichiometric modelling predicts host-based antiviral targets against Chikungunya, Dengue and Zika viruses.
Aller S; Scott A; Sarkar-Tyson M; Soyer OS
J R Soc Interface; 2018 Sep; 15(146):. PubMed ID: 30209043
[TBL] [Abstract][Full Text] [Related]
9. Host Cell Targets for Unconventional Antivirals against RNA Viruses.
Roa-Linares VC; Escudero-Flórez M; Vicente-Manzanares M; Gallego-Gómez JC
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992484
[TBL] [Abstract][Full Text] [Related]
10. Broad-spectrum antivirals against viral fusion.
Vigant F; Santos NC; Lee B
Nat Rev Microbiol; 2015 Jul; 13(7):426-37. PubMed ID: 26075364
[TBL] [Abstract][Full Text] [Related]
11. Assessing the potential of repurposing ion channel inhibitors to treat emerging viral diseases and the role of this host factor in virus replication.
Russell T; Gangotia D; Barry G
Biomed Pharmacother; 2022 Dec; 156():113850. PubMed ID: 36411658
[TBL] [Abstract][Full Text] [Related]
12. RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.
Lesch M; Luckner M; Meyer M; Weege F; Gravenstein I; Raftery M; Sieben C; Martin-Sancho L; Imai-Matsushima A; Welke RW; Frise R; Barclay W; Schönrich G; Herrmann A; Meyer TF; Karlas A
PLoS Pathog; 2019 Mar; 15(3):e1007601. PubMed ID: 30883607
[TBL] [Abstract][Full Text] [Related]
13. Recent highlights in the development of new antiviral drugs.
De Clercq E
Curr Opin Microbiol; 2005 Oct; 8(5):552-60. PubMed ID: 16125443
[TBL] [Abstract][Full Text] [Related]
14. Safe-in-Man Broad Spectrum Antiviral Agents.
Yao R; Ianevski A; Kainov D
Adv Exp Med Biol; 2021; 1322():313-337. PubMed ID: 34258746
[TBL] [Abstract][Full Text] [Related]
15. Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells.
Klintworth A; Nolden T; Westhaus S; Rohrmann K; David S; Manns MP; Finke S; Ciesek S; von Hahn T
Antiviral Res; 2015 Dec; 124():122-31. PubMed ID: 26542648
[TBL] [Abstract][Full Text] [Related]
16. Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Raghuvanshi R; Bharate SB
J Med Chem; 2022 Jan; 65(2):893-921. PubMed ID: 33539089
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing for new, efficient, broad spectrum antivirals.
García-Serradilla M; Risco C; Pacheco B
Virus Res; 2019 Apr; 264():22-31. PubMed ID: 30794895
[TBL] [Abstract][Full Text] [Related]
18. Intervention strategies for emerging viruses: use of antivirals.
Debing Y; Jochmans D; Neyts J
Curr Opin Virol; 2013 Apr; 3(2):217-24. PubMed ID: 23562753
[TBL] [Abstract][Full Text] [Related]
19. The future of antivirals: broad-spectrum inhibitors.
Debing Y; Neyts J; Delang L
Curr Opin Infect Dis; 2015 Dec; 28(6):596-602. PubMed ID: 26524332
[TBL] [Abstract][Full Text] [Related]
20. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.
Johansen LM; DeWald LE; Shoemaker CJ; Hoffstrom BG; Lear-Rooney CM; Stossel A; Nelson E; Delos SE; Simmons JA; Grenier JM; Pierce LT; Pajouhesh H; Lehár J; Hensley LE; Glass PJ; White JM; Olinger GG
Sci Transl Med; 2015 Jun; 7(290):290ra89. PubMed ID: 26041706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
